MedTrace Logo

Safety and Efficacy Study of Mesenchymal Stem Cell in Treating Kidney Fibrosis

NCT03460223 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-03-09

No results posted yet for this study

Summary

In progressive kidney diseases, fibrosis represents the common pathway to end-stage kidney failure. The potential for stem cells to treat kidney failure was recently confirmed. Particularly, mesenchymal stem cell (MSC) has been demonstrated to protect kidney function and alleviating renal injury in these patients. Therefore, the investigators propose a hypothesis that MSCs (MSC) can also improve the disease conditions of kidney fibrosis patients, particularly reducing the decompensated conditions in these patients.

Conditions

  • Renal Cirrhosis

Interventions

BIOLOGICAL

MSC

conventional plus MSC or placebo treatment

Sponsors & Collaborators

  • Nanjing Medical University

    lead OTHER

Principal Investigators

  • Jinhai Tang, M.D, PH.D · Nanjing Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-01
Primary Completion
2020-03-01
Completion
2020-09-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03460223 on ClinicalTrials.gov